Orladeyo (Berotralstat Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Orladeyo (Berotralstat Hydrochloride) by Biocryst: FDA Orange Book core substance LOE 2040-05-01, 0 AB generics, $131.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiocryst
FDA Application & PathwayN214094 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-01
Last Listed Patent or Exclusivity Date2040-05-01
Orange Book Patents (*PED Extensions)32 patents (16 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$131.0M
2024 Medicare Part D Spend$77.9M
2024 Medicaid Spend$53.1M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 20.2% 2-yr change)